
Merck KGaA to Acquire Bio-Techne in $11.3 Billion Life Sciences Deal
Merck KGaA has entered a definitive agreement to acquire Minneapolis-based Bio-Techne for $73 per share in cash. The deal, valued at approximately $11.3 billion, secures the German science giant a stronger foothold in high-growth markets including multi-omics, spatial biology, and advanced cell and gene therapy.


























